fbpx

Hope in treatment for metastatic uveal melanoma

For the first time, a drug has a real positive impact on patients with metastatic uveal melanoma, a disease often qualified as “untreatable.”

 

The good news came from Memorial Sloan-Kettering Cancer Center, whose research results were presented at the 49th annual meeting of the American Society of Clinical Oncology. Researchers found that progression-free survival in patients treated with selumetinib was nearly 16 weeks, and half of these patients experienced tumour shrinkage, with 15% achieving major shrinkage.

 

In comparison, patients treated with temozolomide, the standard chemotherapy, had seven weeks of progression-free survival and no tumour shrinkage. Selumetinib also lengthened overall survival to 10.8 months versus 9.4 months with temozolomide.

 

“This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients,” said lead author Richard D. Carvajal.

Source: http://www.mskcc.org/pressroom/press/new-therapy-shown-improve-progression-free-survival-and-shrink-tumors-rare-first-time

Featured Posts

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read More

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read More

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read More

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read More

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more